Skip to main content
Erschienen in: Rheumatology International 7/2013

01.07.2013 | Original Article

Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker

verfasst von: Sang-Hoon Lee, Eun Jung Lee, Sang Wan Chung, Ran Song, Joo-Young Moon, Sang-Ho Lee, Sung-Jig Lim, Yeon-Ah Lee, Seung-Jae Hong, Hyung-In Yang

Erschienen in: Rheumatology International | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the spine and sacroiliac joint and rarely the kidneys. This study aimed to define the clinical and histological features and biology of renal disease in AS. We reviewed the medical records of 681 patients diagnosed with AS from November 2008 to November 2009. Baseline characteristics and laboratory and urinalysis results were reviewed. We identified patients with proteinuria or hematuria and analyzed their risk factors. After providing informed consent, 6 patients underwent a renal biopsy to determine the cause of proteinuria or hematuria. Of the 681 enrolled patients, 547 were men and 134 were women; 81 % were HLA B27 positive, and 8 % had abnormal urinalysis findings (proteinuria, 5.9 %; hematuria, 2.8 %; both, 0.7 %). Incidences of peripheral arthritis and uveitis were 29 % and 18.6 %, respectively. Immunoglobulin (Ig)A and uric acid levels were significantly different between patients with and without proteinuria. Erythrocyte sedimentation rate (ESR), total cholesterol, creatinine, and C-reactive protein (CRP) levels were not statistically significantly different between the 2 groups nor were there any significant differences in IgA, uric acid, ESR, total cholesterol, creatinine, and CRP levels between patients with and without hematuria. Six patients who had >1 g/day proteinuria underwent a renal biopsy; 2 were diagnosed with IgA nephropathy, 1 with amyloidosis, and 3 with non-specific glomerulonephropathy. In the amyloidosis patient, severe proteinuria was the dominant feature. For patients with renal amyloidosis and other forms of glomerulonephritis who initially had normal creatinine levels, tumor necrosis factor (TNF)-alpha blocker therapy resolved proteinuria, but this was not the case for patients with initial renal insufficiency. Renal involvement is not a rare complication of AS, and prognoses differ depending on kidney pathology. Serum levels of uric acid and IgA may predict renal involvement in AS. In cases where abnormal urine sediment is identified, renal biopsy is required to determine prognosis and decide the treatment protocol. Baseline serum creatinine level is important for predicting treatment response.
Literatur
1.
Zurück zum Zitat Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61(suppl 3):iii8–iii18PubMed Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61(suppl 3):iii8–iii18PubMed
2.
Zurück zum Zitat Lawrence RC, Helmick CG, Arnett FC et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthr Rheum 41:778–799CrossRef Lawrence RC, Helmick CG, Arnett FC et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthr Rheum 41:778–799CrossRef
3.
Zurück zum Zitat Khan MA (1995) HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol 7:263–269PubMedCrossRef Khan MA (1995) HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol 7:263–269PubMedCrossRef
4.
Zurück zum Zitat Braun J, Bollow M, Remlinger G et al (1998) Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthr Rheum 41:58–67CrossRef Braun J, Bollow M, Remlinger G et al (1998) Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthr Rheum 41:58–67CrossRef
5.
Zurück zum Zitat Ng SC, Liao Z, Yu DT et al (2007) Epidemiology of spondyloarthritis in the People’s Republic of China: review of the literature and commentary. Semin Arthr Rheum 37:39–47CrossRef Ng SC, Liao Z, Yu DT et al (2007) Epidemiology of spondyloarthritis in the People’s Republic of China: review of the literature and commentary. Semin Arthr Rheum 37:39–47CrossRef
6.
Zurück zum Zitat Helmick CG, Felson DT, Lawrence RC et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthr Rheum 58:15–25CrossRef Helmick CG, Felson DT, Lawrence RC et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthr Rheum 58:15–25CrossRef
7.
Zurück zum Zitat El Maghraoui A (2004) Ankylosing spondylitis. Press Med 33:1459–1464CrossRef El Maghraoui A (2004) Ankylosing spondylitis. Press Med 33:1459–1464CrossRef
8.
Zurück zum Zitat Elewaut D, Matucci-Cerini M (2009) Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology(Oxford) 48:1029–1035CrossRef Elewaut D, Matucci-Cerini M (2009) Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology(Oxford) 48:1029–1035CrossRef
9.
Zurück zum Zitat El Maghraoui A (2011) Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 22:554–560 (Review) El Maghraoui A (2011) Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 22:554–560 (Review)
10.
Zurück zum Zitat Vilar MJP, Cury SE, Ferraz MB, Sesso R, Atra E (1997) Renal abnormalities in ankylosing spondylitis. Scand J Rheumatol 26:19–23PubMedCrossRef Vilar MJP, Cury SE, Ferraz MB, Sesso R, Atra E (1997) Renal abnormalities in ankylosing spondylitis. Scand J Rheumatol 26:19–23PubMedCrossRef
11.
Zurück zum Zitat Nabokov AV, Shabunin MA, Smirnov AV (1996) Renal involvement in ankylosing spondylitis (Bechterew’s disease). Nephrol Dial Transpl 11:1172–1175CrossRef Nabokov AV, Shabunin MA, Smirnov AV (1996) Renal involvement in ankylosing spondylitis (Bechterew’s disease). Nephrol Dial Transpl 11:1172–1175CrossRef
12.
Zurück zum Zitat Strobel ES, Fritschka E (1998) Reanl diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol 17:524–530PubMedCrossRef Strobel ES, Fritschka E (1998) Reanl diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol 17:524–530PubMedCrossRef
13.
Zurück zum Zitat Singh G, Kumari N, Aggarwal A, Krishnani N, Misra R (2007) Prevalence of subclinical amyloidosis in ankylosing spondylitis. J Rheumatol 34:371–373PubMed Singh G, Kumari N, Aggarwal A, Krishnani N, Misra R (2007) Prevalence of subclinical amyloidosis in ankylosing spondylitis. J Rheumatol 34:371–373PubMed
14.
Zurück zum Zitat Lehtinen K (1993) Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 52:174–176PubMedCrossRef Lehtinen K (1993) Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 52:174–176PubMedCrossRef
15.
Zurück zum Zitat Kobak S, Oksel F, Kabasakal Y, Doganavsargil E (2007) Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol 26:2191–2194PubMedCrossRef Kobak S, Oksel F, Kabasakal Y, Doganavsargil E (2007) Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol 26:2191–2194PubMedCrossRef
Metadaten
Titel
Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker
verfasst von
Sang-Hoon Lee
Eun Jung Lee
Sang Wan Chung
Ran Song
Joo-Young Moon
Sang-Ho Lee
Sung-Jig Lim
Yeon-Ah Lee
Seung-Jae Hong
Hyung-In Yang
Publikationsdatum
01.07.2013
Verlag
Springer-Verlag
Erschienen in
Rheumatology International / Ausgabe 7/2013
Print ISSN: 0172-8172
Elektronische ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2624-9

Weitere Artikel der Ausgabe 7/2013

Rheumatology International 7/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.